Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 3/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060427 | 0.88 | MEN1 (0.53) | MEN1KMT2ATMPRSS4IDO1DEGS1 | |
| SCHEMBL1484026 | 0.88 | MEN1 (0.53) | MEN1KMT2ATMPRSS4IDO1DEGS1 | |
| SCHEMBL25990087 | 0.82 | MEN1 (0.48) | MEN1KMT2ATMPRSS4IDO1DEGS1 | |
| SCHEMBL1430551 | 0.80 | KMT2A (0.57) | MEN1KMT2ATMPRSS4L3MBTL1IDO1 | |
| SCHEMBL19116806 | 0.78 | SMN1; SMN2 (0.51) | MEN1KMT2ATMPRSS4L3MBTL1DEGS1 | |
| SCHEMBL3715011 | 0.78 | MEN1 (0.58) | MEN1KMT2ATMPRSS4IDO1DEGS1 | |
| SCHEMBL2323680 | 0.77 | RAB9A (0.52) | MEN1KMT2AMAPK1 | |
| SCHEMBL6610291 | 0.76 | MEN1 (0.57) | MEN1KMT2ATMPRSS4IDO1DEGS1 | |
| SCHEMBL17538666 | 0.76 | MAPT (0.56) | MEN1KMT2ATMPRSS4L3MBTL1IDO1 | |
| SCHEMBL1428781 | 0.76 | USP30 (0.54) | MEN1KMT2ATMPRSS4DEGS1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314103-B2 | Pyridyl derivatives, their preparation and use | Piramal Enterprises Limited (IN) | 2012-11-20 | — | — | US | disclosed |
| US-20110077252-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | Piramal Enterprises Limited (IN) | 2011-03-31 | — | — | US | disclosed |
| WO-2009019656-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077252-A1 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE | HIF1AN, HIF1A, MTOR | MEN1 4391/4885KMT2A 3868/4885TMPRSS4 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.